Avalo Therapeutics (NASDAQ: AVTX) insider transactions

In the twelve months to 10 November 2026, executives and directors of Avalo Therapeutics reported 43 open-market sales of 437,552 shares ($8.5m) and 0 open-market purchases, by 6 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Avalo Therapeutics shares reported on Form 4
Date	Insider	Role	Transaction	Shares	Price	Held after	Filing
16 September 2026	Sullivan Christopher Ryan	Chief Financial Officer	Option exercise, 10b5-1 plan	+12,394	$9.88	52,294	Form 4
16 September 2026	Sullivan Christopher Ryan	Chief Financial Officer	Open-market sale, 10b5-1 plan	−12,394	$16.33	39,900	Form 4
10 September 2026	Sullivan Christopher Ryan	Chief Financial Officer	Option exercise, 10b5-1 plan	+10,185	$8.04	50,085	Form 4
10 September 2026	Sullivan Christopher Ryan	Chief Financial Officer	Open-market sale, 10b5-1 plan	−10,185	$17.62	39,900	Form 4
28 August 2026	Doyle Mittie	Chief Medical Officer	Option exercise, 10b5-1 plan	+679	$8.04	52,455	Form 4
28 August 2026	Doyle Mittie	Chief Medical Officer	Open-market sale, 10b5-1 plan	−679	$20.00	51,776	Form 4
18 August 2026	Sullivan Christopher Ryan	Chief Financial Officer	Option exercise, 10b5-1 plan	+31,031	$9.88	70,931	Form 4
18 August 2026	Sullivan Christopher Ryan	Chief Financial Officer	Open-market sale, 10b5-1 plan	−31,031	$20.05	39,900	Form 4
17 August 2026	Sullivan Christopher Ryan	Chief Financial Officer	Option exercise, 10b5-1 plan	+37,945	$9.88	78,718	Form 4
17 August 2026	Sullivan Christopher Ryan	Chief Financial Officer	Option exercise, 10b5-1 plan	+2,876	$9.88	81,594	Form 4
17 August 2026	Sullivan Christopher Ryan	Chief Financial Officer	Open-market sale, 10b5-1 plan	−37,945	$19.85	43,649	Form 4
17 August 2026	Sullivan Christopher Ryan	Chief Financial Officer	Open-market sale, 10b5-1 plan	−3,749	$19.94	39,900	Form 4
17 August 2026	Doyle Mittie	Chief Medical Officer	Option exercise, 10b5-1 plan	+1,000	$12.65	52,776	Form 4
17 August 2026	Doyle Mittie	Chief Medical Officer	Open-market sale, 10b5-1 plan	−1,000	$20.00	51,776	Form 4
11 August 2026	Riley Jennifer	Chief Strategy Officer	Open-market sale	−2,655	$19.59	37,041	Form 4
10 August 2026	Doyle Mittie	Chief Medical Officer	Option exercise, 10b5-1 plan	+679	$8.04	52,455	Form 4
10 August 2026	Doyle Mittie	Chief Medical Officer	Open-market sale, 10b5-1 plan	−679	$20.00	51,776	Form 4
27 July 2026	Doyle Mittie	Chief Medical Officer	Option exercise, 10b5-1 plan	+1,000	$12.65	52,776	Form 4
27 July 2026	Doyle Mittie	Chief Medical Officer	Open-market sale, 10b5-1 plan	−1,000	$20.00	51,776	Form 4
30 June 2026	Doyle Mittie	Chief Medical Officer	Option exercise, 10b5-1 plan	+2,875	$12.65	54,651	Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Avalo Therapeutics page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.